Ginkgo Bioworks CFO Steven Coen sells $36,045 in stock

CFO of Ginkgo Bioworks, Steven Coen, sold 2,403 shares of the company's Class A Common Stock on October 5, 2026, for a total of $36,045, with each share sold at $15.00. The transaction adhered to a pre-approved sales plan to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Despite the stock's current price of $11.47, which is below the transaction price, it is considered undervalued according to InvestingPro's analysis.

Following the sale, Coen's beneficial ownership of Ginkgo Bioworks Holdings, Inc. Class A Common Stock increased to 49,448 shares. Ginkgo Bioworks reported a revenue decline in its Q2 2026 financial results, with revenue falling to $20 million, a 48% decrease from the previous year, while maintaining an adjusted loss of $0.92 per share, better than expected.

The company continues to invest in autonomous labs and reported having $389 million in total liquidity, with a cash burn guidance of $125 million to $150 million for the year. Analysts have expressed concerns about Ginkgo's growth trajectory, with some downgrading the stock and reducing price targets.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.